PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Pl...

por Reck, Martin, Paz-Ares, Luis G., de Marinis, Filippo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, John, William, Zimmermann, Annamaria H., Visseren-Grul, Carla, Gridelli, Cesare
Publicado 2014

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

por Nakagawa, Kazuhiko, Nadal, Ernest, Garon, Edward B., Nishio, Makoto, Seto, Takashi, Yamamoto, Nobuyuki, Park, Keunchil, Shih, Jin-Yuan, Paz-Ares, Luis, Frimodt-Moller, Bente, Zimmermann, Annamaria H., Wijayawardana, Sameera, Visseren-Grul, Carla, Reck, Martin
Publicado 2021

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

por de Wit, Ronald, Powles, Thomas, Castellano, Daniel, Necchi, Andrea, Lee, Jae‐Lyun, van der Heijden, Michiel S., Matsubara, Nobuaki, Bamias, Aristotelis, Fléchon, Aude, Sternberg, Cora N., Drakaki, Alexandra, Yu, Evan Y., Zimmermann, Annamaria H., Long, Amanda, Walgren, Richard A., Gao, Ling, Bell‐McGuinn, Katherine M., Petrylak, Daniel P.
Publicado 2022

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung c...

por Garon, Edward B, Scagliotti, Giorgio Vittorio, Gautschi, Oliver, Reck, Martin, Thomas, Michael, Iglesias Docampo, Lara, Kalofonos, Haralabos, Kim, Joo-Hang, Gans, Steven, Brustugun, Odd Terje, Orlov, Sergey V, Cuyun Carter, Gebra, Zimmermann, Annamaria H, Oton, Ana B, Alexandris, Ekaterine, Lee, Pablo, Wolff, Katharina, Stefaniak, Victoria Jennifer, Socinski, Mark A, Pérol, Maurice
Publicado 2020